L-Asparaginase is used for the treatment of acute leukemias, but is sometimes ineffective or associated with severe sideeffects. We report here that the enzyme arginine deiminase is approximately 100-fold more potent than L-asparaginase in inhibiting the proliferation of cultured human lymphatic leukemia cell lines while it appears to be less effective in leukemia cells of myeloid origin. The inhibition of cell proliferation involves cell growth arrest in the G 1 -and/or S-phase and eventually apoptotic cell death. Our results suggest the possibility of a future use of arginine deiminase for the therapy of leukemia. Leukemia (2000) 14, 826-829.
Introduction
L-Asparaginase is probably the best-known and most important growth-inhibitory enzyme in clinical oncology. It is used successfully for the treatment of acute leukemias and certain lymphomas. However, asparaginase treatment is sometimes accompanied by serious side-effects including anaphylactic shock, coagulopathies as well as liver and pancreatic toxicity. 1 In addition, in some patients, the enzyme appears to be ineffective. These properties outline the need for alternative treatments.
We have previously found a growth-inhibitory protein in supernatants of cultured cells contaminated by mycoplasmas. By purifying and sequencing this protein, we were able to demonstrate that it was identical with mycoplasma-derived arginine deiminase. 2 Arginine deiminase (EC 3.5.3.6) is synthesized by various microorganisms with the highest amounts being produced by Mycoplasma arginini (data not shown). It catalyzes the hydrolysis of L-arginine to L-citrulline. The resulting depletion of arginine is thought to be responsible for its growth-inhibitory activities.
3,4 Indeed, we were able to demonstrate that recombinant arginine deiminase inhibits the proliferation of cultured vascular endothelial cells in a potent manner (unpublished) . Others have shown that arginine deiminase can also inhibit the growth of cells derived from solid malignancies in vitro [3] [4] [5] [6] [7] and in vivo. 8 In addition, arginine deiminase appears to have few systemic side-effects in vivo. 8 These data suggested to us that arginine deiminase might have clinical potential as an inhibitor of leukemia proliferation, where it could replace asparaginase in cases of severe side-effects or ineffectiveness. In the present study, we have examined therefore whether arginine deiminase purified from Mycoplasma arginini could inhibit the proliferation of cultured cells derived from acute human leukemia and if so, by which mechanisms this might occur. 
Materials and methods

Materials
Human cell lines derived from acute pediatric T-(Jurkat) or B-(Tanoue) leukemia and from adult acute M2 myeloid leukemia (HL-60) were from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Fresh lymphoblasts isolated by cell sorter from the blood of children with acute lymphatic leukemia were kindly donated by Dr WD Ludwig (Robert-Rö ssle-Klinik der Charité, Berlin, Germany). Mycoplasma arginini (ATCC 23838) was purchased from the American Type Culture Collection (ATCC). E. coli-derived L-asparaginase (specific activity: 80 U/mg protein) was from Boehringer Mannheim (Mannheim, Germany) and was equally active in inhibiting the proliferation of cultured cells derived from leukemia and various solid malignancies (data not shown).
Purification of arginine deiminase from Mycoplasma
Mycoplasma arginini was cultured aerobically for 72 h at 37°C in 2 l of Bacto PPLO broth (Difco, Detroit, MI, USA) (pH 7.0) supplemented with L-arginine (1.0%), horse serum (Biochrom, Berlin, Germany) (20%), yeast extract (Difco) (2.5%), and penicillin G (2000 U/ml). The cells were harvested by centrifugation (15 000 g for 20 min) and washed twice with phosphate-buffered saline (PBS, pH 7.5). The cell pellet was resuspended in 24 ml of potassium phosphate buffer (10 mM, pH 7.0), and sonicated for 15 min in an ice bath. The cytosol fractions were collected by centrifugation (1 h, 100 000 g) at 4°C. The cell extract was subjected to anion-exchange chromatography using a Q Sepharose Fast Flow column (Pharmacia, Sweden) (1 × 4 cm), previously equilibrated with buffer A (ie potassium phosphate buffer (10 mM, pH 7.0)). The loaded column was washed with buffer A and then eluted with a linear gradient of 0-0.5 M NaCl in 100 ml buffer A at a flow rate of 20 ml/h. The active fractions obtained from the anion-exchange column were pooled, and applied to an arginine-Sepharose 4B column (Pharmacia, Uppsala, Sweden) (1 × 4 cm) equilibrated with buffer A. The column was washed with buffer A and then eluted with a linear gradient of 0-0.5 M NaCl in 100 ml buffer A at a flow rate of 20 ml/h. All purification procedures were carried out at 4°C. The purity of arginine deiminase was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on polyacrylamide gels (10%). Arginine deiminase concentration was estimated from the intensities of Coomassie Brilliant Blue-stained protein bands on SDS-PAGE using bovine serum albumin as the standard.
Arginine deiminase determination
Arginine deiminase activity was assayed as described.
3 0.5 ml of a reaction mixture, consisting of L-arginine (50 mM), potass-ium phosphate (0.1 M, pH 7.0) and an enzyme sample, was incubated at 37°C for 3 h, and the reaction was stopped by adding 0.5 ml of a 1:3 mixture (v/v) of concentrated H 2 SO 4 and H 3 PO 4 . The amount of citrulline formed during incubation was determined by the formation of a colored reaction product with diacetyl monoxime. 9 One unit of enzyme activity was defined as the amount of enzyme which converted 1 mol of L-arginine to L-citrulline per minute in the assay conditions, and approximately 10-20 ng of arginine deiminase corresponds to 1 unit.
In addition to enzymatic activity, we verified the bioactivity of each batch of purified arginine deiminase prior to using the cell proliferation assay.
Cell proliferation assay
All cells were maintained in RPMI 1640 medium containing fetal calf serum (10%), amphotericin ␤ (1.25 g/ml), penicillin (100 U/ml) and streptomycin (100 g/ml). The test cells were inoculated in triplicate on 24-well microplates containing 0.5 ml of culture medium at a density of 1.0 × 10 4 cells/well. The cultures then received various concentrations of arginine deiminase previously sterilized by filtration. After 3 to 6 days in culture, cells were counted with a Coulter particle counter (Beckman Coulter, Krefeld, Germany).
Cell cycle analysis
Leukemia cells (5.0 × 10 5 in 5 ml culture medium) were inubated for 3 days with arginine deiminase at a final concentration of 50 ng/ml or only in growth medium (controls). Cells were then incubated for 30 min with 5-bromo-2Ј-deoxyuridine (BrdU, Sigma) (10 M), harvested by centrifugation and fixed in 99% ethanol. For flow cytometric analysis of cell cycle distribution, fixed cells were centrifuged, washed in NaCl (0.9%), and incubated in a pepsin solution (0.5% pepsin (1000 U/g) in 0.055 N HCl, pH 1.8) for 10 min at 37°C to isolate the nuclei. Nuclei were washed again in saline and 2 N HCl was added for 30 min at 21°C to partially denature DNA. Afterwards nuclei were washed once in NaCl (0.9%) and once in PBS-Tween (0.05%), then incubated with antiBrdU mouse IgG (Becton Dickinson, 1:20 in PBS-Tween) for 30 min at 4°C in the dark, washed twice in PBS-Tween (0.05%)-BSA (1%), and incubated with FITC-conjugated goat anti-mouse IgG (DuPont, Bad Homburg, Germany, 1:100 in PBS-Tween-BSA) for 30 min at 4°C in the dark. Finally, they were washed in PBS-Tween again, resuspended in PBS and stained with 25 M propidium iodide (PI) (in 0.1 M Tris, 0.1 M NaCl, pH 7.5). Green (FITC) and red (PI) fluorescence after 488 nm laser excitation were recorded in a FACScan flow cytometer (Becton Dickinson, Heidelberg, Germany) and plotted in two-parameter histograms. Five thousand events were recorded, the coefficient of variation (CV) of the DNA-histograms being about 5%. Cell cycle fractions were determined with the help of windows on the scattergrams. 10 
Apoptosis assays
For the terminal deoxynucleotidyl transferase-mediated dUTPbiotin nick end labeling (TUNEL) method, leukemia cells were seeded at a density of 1 × 10 4 /well on to 4-well culture slides (Falcon, NJ, USA). After 12 h, they received arginine deiminase (200 ng/ml) or buffer only (controls), and were incubated for 3 days. Cells were then collected by centrifugation, airLeukemia dried and fixed on slides with paraformaldehyde (4% in PBS, pH 7.0). Slides were rinsed, permeabilized for 2 min at 21°C in 0.1% sodium citrate containing 0.1% Triton-X 100 and washed twice with PBS. Semi-dry slides were incubated in a humidified chamber for 1 h at 37°C with 40 l of TUNEL mixture (Boehringer Mannheim, Germany).
For nuclear staining, cells labeled by the TUNEL assay were stained by incubation for 20 min at 21°C with 4Ј-6-diamidino-2-phenylindole (DAPI, Sigma, Steinheim, Germany) (2 g/ml), rinsed with PBS, exposed to 20 l of anti-fade medium (DABCO (Sigma), 2.5% (w/v) in PBS containing 50% glycerol), sealed with a cover slip and evaluated under a fluorescence microscope.
Results
Purification of arginine deiminase
The cell extract of M. arginini was subjected to anionexchange chromatography, and active fractions were pooled and applied to an arginine-Sepharose 4B affinity column. Active enzyme adsorbed to the column was eluted at about 0.075 M NaCl. The purified arginine deiminase gave a single Mr 45 kDa protein band when analyzed with SDS-PAGE under reducing (Figure 1 ) or non-reducing (data not shown) conditions. We calculated a yield of about 0.2 mg of pure arginine deiminase from 1 l culture of M. arginini. The enzyme was stored at 4°C until further use and was active for up to 60 days of storage. Figure 2a demonstrates the effect of arginine deiminase on the growth of fresh lymphoblasts from two children with acute common or T lymphatic leukemia and on cultured cells
Potency as compared with L-asparaginase
Figure 1
Analysis of purified arginine deiminase by SDS-polyacrylamide gel electrophoresis was done as described under Materials and methods. Lane 1, marker proteins; lane 2, purified arginine deiminase. Molecular weights are indicated in kDa.
Leukemia
Figure 2
Effect of increasing concentrations of arginine deiminase on the proliferation of various leukemia cell lines and comparison with asparaginase. derived from pediatric acute T-(Jurkat) or B-(Tanoue) lymphatic leukemia and adult acute M2 myeloid leukemia (HL-60). Arginine deiminase inhibited proliferation of both lymphatic cell lines in a potent manner with half-maximal inhibition achieved with only 5-10 ng/ml while it appeared to be somewhat weaker in the fresh lymphoblasts. Arginine deiminase had little effect on the proliferation of the myeloid cell line. The latter effect could not be potentiated by repeated application of arginine deiminase or by extending culture time. When compared to L-asparaginase, which is used for leukemia therapy, arginine deiminase was about 100 to 200-fold more potent in inhibiting proliferation of the lymphatic leukemia cell line (Figure 2b ).
Effect on cell cycle distribution
To determine whether the arginine deiminase-induced inhibition of leukemia cell proliferation involved changes in cell cycle, we performed flow-cytometric analysis of cells exposed to arginine deiminase or not. In both lymphatic leukemia cell lines (Jurkat and Tanoue), arginine deiminase treatment decreased the fraction of active S-phase (S) cells (ie cells with an S-phase DNA content that incorporate BrdU) with a corresponding increase of the inactive S-phase (S 0 ) cells (ie cells that do not incorporate BrdU) ( Table 1 ). In the B-leukemia cells (Tanoue), there was an additional arginine deiminaseinduced increase of G 1 -phase cells. Thus, arginine deiminase arrests cell cycle by a preferential shift of the cells into S 0 -phase, or both S 0 -and G 1 -phase.
Induction of apoptotic cell death
As changes in cell cycle are often associated with cell death, 11, 12 we examined the effect of arginine deiminase on apoptosis of the lymphatic leukemia cell lines (Jurkat and Tanoue) using the DNA-specific fluorochrome DAPI staining and TUNEL assay. Arginine deiminase-treated cells appeared smaller, exhibiting cell shrinkage, nuclear and chromation condensation as compared to untreated control cells by DAPI staining. Analysis by TUNEL assay revealed nuclear DNA fragmentation in more than 50% of the treated cells as compared to less than 5% in the untreated controls (not shown).
Discussion
Arginine deiminase is known to inhibit the growth of various solid tumors in vivo. [3] [4] [5] [6] [7] [8] 13 Here, we have demonstrated for the first time that arginine deiminase inhibits the proliferation of fresh or cultured lymphatic leukemia cells (Figure 2) . A time course study showed that arginine deiminase inhibited cell growth as early as the 2nd day after treatment, and its inhibitory activity was increased by prolonged enzyme treatment, eventually leading to cell death. To characterize the cytostatic activity of arginine deiminase, a cell cycle analysis was performed, which revealed that the treated cells were arrested in G 1 -, and/or in an inactive S-phase ( Table 1 ). The latter phenomenon was observed in both Jurkat and Tanoue cells where exposure to arginine deiminase obviously allowed progression into S-phase, but prevented a significant proportion of S-phase cells from completing replication, and thus caused them to become inactive within the S-phase. This indicates that transition into a quiescent state is not only restricted to the G 1 -phase as classically assumed, 12, 13 but is also possible in the S-phase. 14 The quiescent cells in the S-phase compartment may have developed due to a general breakdown of cellular energy metabolism, leading to a cessation of cell cycle progression. This goes with the observation that in several other human tumor cell lines, inactive S-phase cells also occur after a few days of incubation under hypoxic conditions, at low pH or in an glucose deficient medium. 15 On exposure to 200 ng/ml of arginine deiminase, we observed Table 1 Effect of arginine deiminase on cell cycle distribution in leukemia cells
Cell line
No treatment (controls) Treatment with arginine deiminase cell shrinkage and nuclear condensation by DAPI staining, and DNA fragmentation by in situ end labeling of DNA breaks with terminal transferase (TUNEL), indicating that arginine deiminase eventually induces apoptosis. More apoptotic cells were observed by prolonging the exposure of Jurkat and Tanoue cells to arginine deiminase, whereas decreasing arginine deiminase concentrations below 200 ng/ml resulted in lower numbers of apoptotic cells. Thus, the induction of apoptosis by arginine deiminase is dose-and time-dependent. It is usually assumed that apoptosis and G 1 arrest are related. 12 We demonstrate here that arginine deminase induces apoptosis in Jurkat cells, where only S-phase arrest was observed (Table  1) , indicating apoptotic mechanism by arginine deiminase in Jurkat cells is obviously independent of the G 1 arrest, which points to a lack of correlation between two endpoints. It is possible that one of the mechanisms by which arginine deiminase induces its inhibitory effects is related to its ability to deplete cells from arginine. In fact, human serum incubated with excess of arginine deiminase purified from Mycoplasma arginini was completely depleted of arginine, as determined by amino acid analysis (data not shown). Our results are supported by the findings of others demonstrating that arginine in the plasma of mice was completely cleared for at least 3 days upon injection of Mycoplama arginini-derived arginine deiminase. 8 Our results show that arginine deiminase inhibits the growth of cultured leukemia cells (Jurkat and Tanoue) at very low concentrations (5-10 ng/ml) while it inhibited that of fresh lymphoblasts at concentrations between 20 and 100 ng/ml. These effective concentrations were about 10-200 times lower than those of asparaginase (Figure 2) , which is the only amino-acid-degrading enzyme currently used for clinical chemotherapy on leukemia. Fugure studies in leukemiabearing studies may demonstrate that arginine deiminase is feasible for in vivo studies. Work of others has suggested that arginine deiminase has few, if any, side-effects in vivo. 8 Therefore, the present study raises the possibility of the future use of arginine deiminase as an anti-leukemic substance.
